Nicole Déglon is research director of the French Atomic Energy Commission (CEA) and deputy director of MIRCen, a pre-clinical imaging platform for drug, cell and gene therapy located in Fontenay-aux-Roses, south of Paris. Dr. Déglon’s research interests include the development of viral-based genetic models of neurodegenerative diseases, the treatment of neurodegenerative diseases from cell transplantation to gene therapy, and investigation of the central nervous system by means of functional and molecular imaging techniques. Dr. Déglon received her education, including a PhD in biochemistry, at the University of Lausanne, Switzerland. Before joining CEA in 2003, she held several research positions at the Gene Therapy Center in Lausanne, at the Salk Institute in San Diego, California, and at the Federal Polytechnic Institute of Lausanne, Switzerland where she developed gene therapy approaches for neurodegenerative diseases.